OBP-801

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
OBP-801
Accession Number
DB12279
Type
Small Molecule
Groups
Investigational
Description

OBP-801 has been used in trials studying the treatment of Solid Tumor.

Structure
Thumb
Synonyms
Not Available
External IDs
YM-753
Categories
UNII
30Q3VS5HZ4
CAS number
328548-11-4
Weight
Average: 473.6
Monoisotopic: 473.165428078
Chemical Formula
C20H31N3O6S2
InChI Key
XFLBOEMFLGLWFF-HDXRNPEWSA-N
InChI
InChI=1S/C20H31N3O6S2/c1-11(2)18-15(24)9-17(26)29-13-6-4-5-7-30-31-10-14(20(28)23-18)22-19(27)12(3)21-16(25)8-13/h4,6,11-15,18,24H,5,7-10H2,1-3H3,(H,21,25)(H,22,27)(H,23,28)/b6-4+/t12-,13-,14-,15+,18-/m1/s1
IUPAC Name
(1S,5S,6R,9S,15E,20R)-5-hydroxy-20-methyl-6-(propan-2-yl)-2-oxa-11,12-dithia-7,19,22-triazabicyclo[7.7.6]docos-15-ene-3,8,18,21-tetrone
SMILES
CC(C)[[email protected]]1NC(=O)[[email protected]]2CSSCC\C=C\[[email protected]](CC(=O)N[[email protected]](C)C(=O)N2)OC(=O)C[[email protected]@H]1O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of OBP-801.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of OBP-801.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of OBP-801.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with OBP-801.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of OBP-801.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of OBP-801.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of OBP-801.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of OBP-801.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of OBP-801.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of OBP-801.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with OBP-801.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of OBP-801.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of OBP-801.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of OBP-801.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of OBP-801.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of OBP-801.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with OBP-801.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of OBP-801.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of OBP-801.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of OBP-801.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
11178958
PubChem Substance
347828548
ChemSpider
9354048
ChEMBL
CHEMBL3126832

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentTumors, Solid1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.637 mg/mLALOGPS
logP0.27ALOGPS
logP-0.16ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)10.84ChemAxon
pKa (Strongest Basic)-2.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area133.83 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity120.29 m3·mol-1ChemAxon
Polarizability47.39 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cyclic depsipeptides. These are natural or synthetic compounds having sequences of amino and hydroxy carboxylic acid residues (usually α-amino and α-hydroxy acids) connected in a ring. The residues are commonly but not necessarily regularly alternating.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Peptidomimetics
Sub Class
Depsipeptides
Direct Parent
Cyclic depsipeptides
Alternative Parents
Dipeptides / Macrolide lactams / Macrolactams / Macrolides and analogues / Alpha amino acids and derivatives / Secondary alcohols / Carboxylic acid esters / Secondary carboxylic acid amides / Lactams / Lactones
show 9 more
Substituents
Alpha-dipeptide / Cyclic depsipeptide / Macrolide lactam / Macrolactam / Macrolide / Alpha-amino acid or derivatives / Carboxamide group / Carboxylic acid ester / Lactam / Lactone
show 18 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:48 / Updated on November 09, 2017 05:04